Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS-model superoxide dismutase 1 (SOD1)(G93A) rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. To test miRNA inhibition in the central nervous system (CNS) as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the CNS and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1(G93A) mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“miRNAs are increasingly recognized as key regulators in ALS pathophysiology, including mitochondrial integrity and neuroinflammation, with miR-155 and miR-206 demonstrating pivotal roles in SOD1G93A models [48,49,50,51].”
From Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis (2026) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inhibiting miR-155 significantly delays disease progression in SOD1 G93A mice (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Work from our lab and others found that miR-155, a glialenriched miRNA, is upregulated in the spinal cords of end-stage ALS model (SOD1 G93A ) mice and human autopsy (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
In the citing paper
“Targeting miR-155 in microglia has shown to be a benefit in models of ALS84,195 and is currently being pursued as a possible therapeutic strategy.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948 · cited 1×
“Since their discovery in 1993 (1), microRNAs (miRNAs) have emerged as key regulators in numerous physiological and pathological processes.”
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204 · cited 1×
“Anti-miRs have been used safely and effectively in the periphery in recent human clinical trials [NCT00688012 and NCT00979927 (20)], and CSF infusion of antisense oligonucleotides designed to lower mRNA has recently been applied to patients with ALS (21).”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826 · cited 3×
“Furthermore, quantification of one of these targets, SHIP1, across the CNS demonstrated a significant increase over saline in all areas assayed (Fig.”
microRNA-155 Regulates the Generation of Immunoglobulin Class-Switched Plasma Cells
Vigorito, E., Perks, K. L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., Das, P. P., Miska, E. A., Rodriguez, A., Bradley, A., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.009 · Cited by 763
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adult-onset neurodegenerative disease characterized by the selective loss of motor neurons in the spinal cord and brain leading to stiffness, severe muscle weakness and death because of respiratory failure typically within 3–5 years of…”
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationJunker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595 · cited 1×
“Our data clearly identify miR-155 as a promising therapeutic target for ALS and may potentially apply more broadly to neurological disorders where miR-155 is increased including multiple sclerosis (23) and in glioblastoma (24).”
MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation
Sonkoly, E., Ståhle, M., & Pivarcsi, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.01.005 · Cited by 523
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506 · cited 3×
“To target miRNAs in the CNS, we delivered anti-miRs directly to the cerebral spinal fluid as previously described for mRNA inhibitors (10).”
InfluentialModulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., & Appel, S. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807419105 · Cited by 466
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350 · cited 1×
“Of those studies that have reported extended disease duration in the mouse model, the weighted mean difference in a meta-analysis was 10%, while we here report a 38% extension in disease duration (22).”
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model
Lee, S., Chu, K., Jung, K., Kim, J. H., Huh, J., Yoon, H., Park, D., Lim, J., Kim, J., Jeon, D., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23588 · Cited by 326
Detecting microRNA binding and siRNA off-target effects from expression data
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008) · Nature Methods · doi:10.1038/nmeth.1267 · Cited by 273
Inhibition of microRNA with antisense oligonucleotides
Esau, C. C. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 257
An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model
Selvamani, A., Sathyan, P., Miranda, R. C., & Sohrabji, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032662 · Cited by 217 · cited 1×
“While other studies have demonstrated anti-miR function in limited sections of cortical tissue (18,19), these data establish a method of widespread inhibition of miRNAs and are the first to show inhibition of miRNAs in the spinal cord.”
MicroRNA-155 contributes to preeclampsia by down-regulating CYR61
Zhang, Y., Diao, Z., Su, L., Sun, H., Li, R., Cui, H., & Hu, Y. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.01.057 · Cited by 166
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
DeVos, S. L., & Miller, T. M. (2013) · Journal of Visualized Experiments · doi:10.3791/50326 · Cited by 165 · cited 1×
“For implantation, mice were anesthetized in a chamber with 5% isoflurane/oxygen mixture and confirmed to be unconscious before being placed in Kopf Model 940 small animal stereotaxic apparatus, fitted with ear bars (29).”
Self-citationMicroRNAs in the immune response
Pedersen, I., & David, M. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.016 · Cited by 139 · cited 1×
“Interestingly, all six of the patient-confirmed upregulated miRNAs (miR-24, miR-142-3p, miR-142-5p, miR-146a, miR-146b and miR-155) are well studied in the context of immunity and inflammation (25,26).”
Hall, J. S., Taylor, J., Valentine, H. R., Irlam, J. J., Eustace, A., Hoskin, P. J., Miller, C. J., & West, C. M. L. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.294 · Cited by 130 · cited 1×
“This is in agreement with published data showing miRNAs to be stable despite extensive degradation of mRNA (11).”
Marsigliante, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1420 · Cited by 97
Wang, X., Zhao, Q., Matta, R., Meng, X., Liu, X., Liu, C.-G., Nelin, L. D., & Liu, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051235 · Cited by 65 · cited 1×
“miR-155 is highly expressed in hematopoietic cells including T cells and monocytes (3) and can serve to promote pro-inflammatory pathways through targeted repression of antiinflammatory mediators including Src homology-2 domaincontaining inositol 5 phosphatase 1 (SHIP1) (4) and suppressor of cytokine signaling-1 (5).”
Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq
Xu, G., Fewell, C., Taylor, C., Deng, N., Hedges, D., Wang, X., Zhang, K., Lacey, M., Zhang, H., Yin, Q., et al. (2010) · RNA · doi:10.1261/rna.2194910 · Cited by 59
Androsavich, J. R., Chau, B. N., Bhat, B., Linsley, P. S., & Walter, N. G. (2012) · RNA · doi:10.1261/rna.033308.112 · Cited by 59
Self-citation
Research works printed but not linked: 2
- Esau, C. (2010) In: Keystone Symposia: Diabetes (Z6). Whistler: British Columbia Canada.
- D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, A., Pietro, C. and Marsigliante, S. (2012) miR-155 4134 Human Molecular Genetics, 2013, Vol. 22, No. 20
Cited by
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik, C. A., S. Drake, S., Zhang, Y., Paradis-Isler, N., Sylvester, A., Amar-Zifkin, A., Douglas, C., Morquette, B., Moore, C. S., & Fournier, A. E. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101664 · Cited by 426
Microglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365
Targeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358
“Our results are consistent with a recent report that anti–miR-155 given in combination both peripherally and into the CNS extended survival in SOD1 mice by 10 days.(54)”
ALS Genes in the Genomic Era and their Implications for FTD
Nguyen, H. P., Van Broeckhoven, C., & van der Zee, J. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.03.001 · Cited by 307
Metadata
- Authors
- Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M.
- Affiliations
- Washington University in St. Louis (US)
- Regulus Therapeutics (United States) (US)
- Corresponding author
- Miller, Timothy M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-04
- Volume
- 22
- Issue
- 20
- Pages
- 4127-4135
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3781640
- OpenAlex
- W2106430667
- Cited by
- 236
- References
- 27
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 15 · 2020: 29 · 2019: 13 · 2018: 30 · 2017: 22 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dana Foundation
- Massachusetts General Hospital
- Edward Mallinckrodt, Jr. Foundation
- National Institutes of Health
- School of Medicine, Stanford University
- National Institute of Neurological Disorders and Stroke (F31NS077781, K08NS062138, K08NS074194, R01NS078398)
- Robert Packard Center for ALS Research, Johns Hopkins University
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- miR-155, amyotrophic lateral sclerosis, anti-miR oligonucleotides, microRNA inhibition, SOD1 G93A mice, survival extension, peritoneal macrophages, spinal cord, therapeutic target, antisense oligonucleotides
- MeSH terms
- Adult, Aged, Amyotrophic Lateral Sclerosis, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Spinal Cord, Superoxide Dismutase, Case-Control Studies, Oligonucleotides, Antisense, MicroRNAs, Mice, Rats, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.